Nanobodies: The "Magic Bullets" in therapeutics, drug delivery and diagnostics

Antibodies represent a well-established class of clinical diagnostics for medical applications as well as essential research and biotechnological tools. Although both polyclonal and monoclonal antibodies are indispensable reagents in basic research and diagnostics but both of them have their limitat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Human antibodies Ročník 28; číslo 1; s. 29
Hlavní autoři: Mir, Manzoor A, Mehraj, Umar, Sheikh, Bashir Ahmad, Hamdani, Syed Suhail
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands 2020
Témata:
ISSN:1875-869X, 1875-869X
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Antibodies represent a well-established class of clinical diagnostics for medical applications as well as essential research and biotechnological tools. Although both polyclonal and monoclonal antibodies are indispensable reagents in basic research and diagnostics but both of them have their limitations. Hence, there is urgent need to develop strategies aimed at production of alternative scaffolds and recombinant antibodies of smaller dimensions that could be easily produced, selected and manipulated. Unlike conventional antibodies, members of Camelidae and sharks produce antibodies composed only of heavy chains with small size, high solubility, thermal stability, refolding capacity and good tissue penetration in vivo. The discovery of these naturally occurring antibodies having only heavy-chain in Camelidae family and their further development into small recombinant nanobodies represents an attractive alternative in drug delivery, diagnostics and imaging. Nanobody derivatives are soluble, stable, versatile, have unique refolding capacities, reduced aggregation tendencies and high-target binding capabilities. They can be genetically customized to target enzymes, transmembrane proteins or molecular interactions. Their ability to recognize recessed antigenic sites has been attributed to their smaller size and the ability of the extended CDR3 loop to quickly penetrate into such epitopes. With the advent of molecular engineering and phage display technology, they can be of potential use in molecular imaging, drug delivery and therapeutics for several major diseases. In this review we present the recent advances in nanobodies for modulating immune functions, for targeting cancers, viruses, toxins and microbes as well as their utility as diagnostic and biosensor tools.
AbstractList Antibodies represent a well-established class of clinical diagnostics for medical applications as well as essential research and biotechnological tools. Although both polyclonal and monoclonal antibodies are indispensable reagents in basic research and diagnostics but both of them have their limitations. Hence, there is urgent need to develop strategies aimed at production of alternative scaffolds and recombinant antibodies of smaller dimensions that could be easily produced, selected and manipulated. Unlike conventional antibodies, members of Camelidae and sharks produce antibodies composed only of heavy chains with small size, high solubility, thermal stability, refolding capacity and good tissue penetration in vivo. The discovery of these naturally occurring antibodies having only heavy-chain in Camelidae family and their further development into small recombinant nanobodies represents an attractive alternative in drug delivery, diagnostics and imaging. Nanobody derivatives are soluble, stable, versatile, have unique refolding capacities, reduced aggregation tendencies and high-target binding capabilities. They can be genetically customized to target enzymes, transmembrane proteins or molecular interactions. Their ability to recognize recessed antigenic sites has been attributed to their smaller size and the ability of the extended CDR3 loop to quickly penetrate into such epitopes. With the advent of molecular engineering and phage display technology, they can be of potential use in molecular imaging, drug delivery and therapeutics for several major diseases. In this review we present the recent advances in nanobodies for modulating immune functions, for targeting cancers, viruses, toxins and microbes as well as their utility as diagnostic and biosensor tools.
Antibodies represent a well-established class of clinical diagnostics for medical applications as well as essential research and biotechnological tools. Although both polyclonal and monoclonal antibodies are indispensable reagents in basic research and diagnostics but both of them have their limitations. Hence, there is urgent need to develop strategies aimed at production of alternative scaffolds and recombinant antibodies of smaller dimensions that could be easily produced, selected and manipulated. Unlike conventional antibodies, members of Camelidae and sharks produce antibodies composed only of heavy chains with small size, high solubility, thermal stability, refolding capacity and good tissue penetration in vivo. The discovery of these naturally occurring antibodies having only heavy-chain in Camelidae family and their further development into small recombinant nanobodies represents an attractive alternative in drug delivery, diagnostics and imaging. Nanobody derivatives are soluble, stable, versatile, have unique refolding capacities, reduced aggregation tendencies and high-target binding capabilities. They can be genetically customized to target enzymes, transmembrane proteins or molecular interactions. Their ability to recognize recessed antigenic sites has been attributed to their smaller size and the ability of the extended CDR3 loop to quickly penetrate into such epitopes. With the advent of molecular engineering and phage display technology, they can be of potential use in molecular imaging, drug delivery and therapeutics for several major diseases. In this review we present the recent advances in nanobodies for modulating immune functions, for targeting cancers, viruses, toxins and microbes as well as their utility as diagnostic and biosensor tools.Antibodies represent a well-established class of clinical diagnostics for medical applications as well as essential research and biotechnological tools. Although both polyclonal and monoclonal antibodies are indispensable reagents in basic research and diagnostics but both of them have their limitations. Hence, there is urgent need to develop strategies aimed at production of alternative scaffolds and recombinant antibodies of smaller dimensions that could be easily produced, selected and manipulated. Unlike conventional antibodies, members of Camelidae and sharks produce antibodies composed only of heavy chains with small size, high solubility, thermal stability, refolding capacity and good tissue penetration in vivo. The discovery of these naturally occurring antibodies having only heavy-chain in Camelidae family and their further development into small recombinant nanobodies represents an attractive alternative in drug delivery, diagnostics and imaging. Nanobody derivatives are soluble, stable, versatile, have unique refolding capacities, reduced aggregation tendencies and high-target binding capabilities. They can be genetically customized to target enzymes, transmembrane proteins or molecular interactions. Their ability to recognize recessed antigenic sites has been attributed to their smaller size and the ability of the extended CDR3 loop to quickly penetrate into such epitopes. With the advent of molecular engineering and phage display technology, they can be of potential use in molecular imaging, drug delivery and therapeutics for several major diseases. In this review we present the recent advances in nanobodies for modulating immune functions, for targeting cancers, viruses, toxins and microbes as well as their utility as diagnostic and biosensor tools.
Author Mir, Manzoor A
Sheikh, Bashir Ahmad
Mehraj, Umar
Hamdani, Syed Suhail
Author_xml – sequence: 1
  givenname: Manzoor A
  surname: Mir
  fullname: Mir, Manzoor A
– sequence: 2
  givenname: Umar
  surname: Mehraj
  fullname: Mehraj, Umar
– sequence: 3
  givenname: Bashir Ahmad
  surname: Sheikh
  fullname: Sheikh, Bashir Ahmad
– sequence: 4
  givenname: Syed Suhail
  surname: Hamdani
  fullname: Hamdani, Syed Suhail
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31322555$$D View this record in MEDLINE/PubMed
BookMark eNpNkMFLwzAYxYNMdE4v_gESdvJgtfmyNIm3bagT5rxM8FbS5FsXaNPZtML-exUneHoP3u-9wzsjg9AEJOSSpbccOL9bTGcJ0ynX6REZMiVFojL9PvjnT8gpZxxACDEkq5UJTdE4j_GerrdIxy-m9JbO-qrCLo6pD7TbYmt22Hfexhvq2r6kDiv_ie2emuCo86YMTfyJz8nxxlQRLw46Im-PD-v5Ilm-Pj3Pp8vEclBdYlLGDVrgEztBlmnnhN4gasuklU4agdqBUswxpjRowQWDghlbyHSTSS5hRK5_d3dt89Fj7PLaR4tVZQI2fcwBMgYqFd-9Ebk6oH1Ro8t3ra9Nu8__PoAv-ftbFw
CitedBy_id crossref_primary_10_1007_s12032_022_01779_9
crossref_primary_10_1016_j_microc_2025_114083
crossref_primary_10_3390_nano11123360
crossref_primary_10_3390_md21090496
crossref_primary_10_1007_s12032_022_01811_y
crossref_primary_10_1039_D5RA03102H
crossref_primary_10_3892_ijmm_2023_5336
crossref_primary_10_1038_s41598_022_27161_3
crossref_primary_10_1007_s12033_023_00700_7
crossref_primary_10_3233_HAB_210443
crossref_primary_10_1007_s12250_021_00436_1
crossref_primary_10_1016_j_pep_2022_106094
crossref_primary_10_1002_art_42273
crossref_primary_10_1089_cbr_2020_3941
crossref_primary_10_1016_j_bbrc_2024_150956
crossref_primary_10_1093_mr_roac126
crossref_primary_10_3389_fmed_2023_1135541
crossref_primary_10_1186_s13075_023_03036_4
crossref_primary_10_1007_s12032_022_01748_2
crossref_primary_10_3390_ijms24031905
crossref_primary_10_1128_Spectrum_00915_21
crossref_primary_10_3233_HAB_200436
crossref_primary_10_1002_wnan_1697
crossref_primary_10_3389_fphar_2024_1510806
crossref_primary_10_3390_vetsci11110533
crossref_primary_10_3390_cells9030741
crossref_primary_10_3390_pharmaceutics13121984
crossref_primary_10_1016_j_drudis_2023_103550
crossref_primary_10_1016_j_intimp_2025_115368
crossref_primary_10_1089_cbr_2021_0389
crossref_primary_10_1016_j_addr_2021_113940
crossref_primary_10_1002_mco2_60
crossref_primary_10_1021_acschembio_5c00329
crossref_primary_10_1007_s00432_022_04515_y
crossref_primary_10_1016_j_molimm_2023_09_005
crossref_primary_10_3389_fimmu_2021_690742
crossref_primary_10_1093_mr_roac119
ContentType Journal Article
DBID NPM
7X8
DOI 10.3233/HAB-190390
DatabaseName PubMed
MEDLINE - Academic
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
EISSN 1875-869X
ExternalDocumentID 31322555
Genre Journal Article
GroupedDBID NPM
7X8
ID FETCH-LOGICAL-c328t-a013aec234c4e169dd59fee9c17c7d7a5e9d2881d11892953512b1acb70f67372
IEDL.DBID 7X8
ISSN 1875-869X
IngestDate Thu Jul 10 18:38:43 EDT 2025
Thu Jan 02 22:59:51 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords diagnostics
chimeric
immunoaffinity chromatography
site directed mutagenesis
cancer
drug delivery
nanobody
Recombinant antibodies
humanized antibodies
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c328t-a013aec234c4e169dd59fee9c17c7d7a5e9d2881d11892953512b1acb70f67372
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 31322555
PQID 2261280551
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2261280551
pubmed_primary_31322555
PublicationCentury 2000
PublicationDate 2020-00-00
PublicationDateYYYYMMDD 2020-01-01
PublicationDate_xml – year: 2020
  text: 2020-00-00
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Human antibodies
PublicationTitleAlternate Hum Antibodies
PublicationYear 2020
Score 2.394184
SecondaryResourceType review_article
Snippet Antibodies represent a well-established class of clinical diagnostics for medical applications as well as essential research and biotechnological tools....
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 29
Title Nanobodies: The "Magic Bullets" in therapeutics, drug delivery and diagnostics
URI https://www.ncbi.nlm.nih.gov/pubmed/31322555
https://www.proquest.com/docview/2261280551
Volume 28
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7UevDiglvdGItHhyaZLDNeRMTipaEHhdzCrFKQpG1awX_vm0mKXgTBSy4hMLy85XvLfA-hG-FhtLbEZJEiMVdgc1SCXQUmsSp2nSLpl01kec6Kgk-6glvTjVWufaJ31LpWrkY-jBzXFQsgwN_P5sRtjXLd1W6FxibqUYAyTquzwt9-AxhOWMqLlpGURpQOwRoIhD_Kg9_RpI8qo73_nmcf7XZ4Ej-0CnCANkx1iHLwmbWs3YDgHQZFwIOxAA-HW67tZoCnFf5x8aq5xXqxesPavLspjU8sKo11O4PnXh-h19HTy-Mz6RYnEEUjtiQCcJ0wKqKxik2Ycq0Tbo3hKsxUpjORGK4jBkgVsguARwmFqC9DoWQWWL-35hhtVXVlThG2MeAVJXXKZBrrFPSO2RTiqlGxVSy0fXS9Fk8Jium6DaIy9aopvwXURyetjMtZy6BROr5IyGWSsz98fY52Ipfj-rLHBepZMEtzibbVx3LaLK78H4dnPhl_AYzit8c
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nanobodies%3A+The+%22Magic+Bullets%22+in+therapeutics%2C+drug+delivery+and+diagnostics&rft.jtitle=Human+antibodies&rft.au=Mir%2C+Manzoor+A&rft.au=Mehraj%2C+Umar&rft.au=Sheikh%2C+Bashir+Ahmad&rft.au=Hamdani%2C+Syed+Suhail&rft.date=2020-01-01&rft.eissn=1875-869X&rft.volume=28&rft.issue=1&rft.spage=29&rft_id=info:doi/10.3233%2FHAB-190390&rft_id=info%3Apmid%2F31322555&rft_id=info%3Apmid%2F31322555&rft.externalDocID=31322555
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1875-869X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1875-869X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1875-869X&client=summon